Skip to main content

Table 1 Characteristics of included studies

From: Impact of Plasmodium falciparum malaria and intermittent preventive treatment of malaria in pregnancy on the risk of malaria in infants: a systematic review

Author, year of publication. Country (references) N Study design IPTp regimens Follow-up duration Measures of malaria in pregnancy Measures of malaria during infancy
Maternal blooda Placental bloodb Placental histologyc parasitaemia Clinical malaria
Tassi Yunga, 2018. Cameroon [34] 80 Cohort None 1 year      
Boudova, 2017. Malawi [40] 473 RCT SP vs CQ vs CQ prophylaxis 2 years
Ruperez, 2016. Benin, Gabon, Tanzania, Mozambique [38] 4247 RCT SP vs MQ 1 year     
Sylvester, 2016. Tanzania [41] 206 Cohort Not reported 2 years     
De Beaudrap, 2016. Uganda [37] 832 Cohort SP 1 year    
Awine, 2016. Ghana [19] 988 RCT SP vs ISTp-AL 1 year     
Apinjoh, 2015. Cameroon [36] 415 Cohort SP 1 year  
Ndibazza, 2013. Uganda [39] 2289 Cohort SP 5 years    
Borgella, 2013. Benin [18] 194 Cohort SP 1 year  
Asante, 2013. Ghana [20] 1855 Cohort SP 1 year     
Le Port, 2011. Benin [35] 550 Cohort SP 1 year      
Bardaji, 2011.Mozambique [16] 997 RCT SP vs placebo 1 year    
Schwarz, 2008. Gabon [17] 527 Cohort None 2.5 years     
Mutabingwa, 2005. Tanzania [21] 453 Cohort SP 1 year      
  1. AL artemether lumefantrine, CQ chloroquine, IPTp intermittent preventive treatment of malaria in pregnancy, ISTp intermittent screening and treatment of malaria in pregnancy, MQ mefloquine, RCT randomized controlled trial, SP sulfadoxine–pyrimethamine
  2. aMalaria detected in maternal blood by microscopy or PCR
  3. bPlacental malaria detected in placental blood by microscopy
  4. cPlacental malaria detected in placental tissue by histology